

ANNIE GUÉRIN
Managing Principal

Phone: 514 394 4484
Mobile: 514 452 1681
annie.guerin@analysisgroup.com

1190 avenue des Canadiens-de-Montréal
Tour Deloitte, Suite 1500
Montreal, Quebec H3B 0G7

Ms. Guérin is a health economist specializing in health economics and outcomes research (HEOR) and real-world evidence. She designs and leads retrospective database studies (claims, electronic health records, registries, and unstructured physician notes), large-scale multi-country chart reviews and surveys, and economic models to inform clinical, policy, and market-access decisions. She has deep expertise in data curation, linkage, and quality assessment across disparate datasets, and applies advanced statistical methods to generate robust, credible evidence. Her methodological work spans comparative and cost effectiveness, patient-reported and preference research, burden of illness, treatment patterns, safety analyses, and predictive modeling, using machine learning and AI to advance risk prediction, patient stratification, treatment optimization, and early identification of unmet needs.

Therapeutic experience includes oncology, hematology, hepatology, dermatology, gastroenterology, rheumatology, neurology, psychiatry, endocrinology, cardiology, and respiratory disease. Ms. Guérin leads HEOR strategy and global evidence generation planning for biopharmaceutical partners, supporting both regulatory (US Food and Drug Administration (FDA) and European Medicines Agency) and payer decision making through value communication materials. She is recognized for developing international, large-scale evidence-generation strategies that balance scientific rigor with real-world feasibility. Ms. Guérin has authored over 100 peer-reviewed publications, frequently presents at scientific conferences, and contributes to advancing HEOR and real-world evidence methodologies.

EDUCATION

- 2005–2008 M.S., economics (*honors*), Université de Sherbrooke, Quebec
Concentration: Pharmacoeconomics/Econometrics
- 2002–2005 B.S., economics (*honors*), Co-op Program, Université de Sherbrooke, Quebec

WORK EXPERIENCE

- 2005–Present Analysis Group/Group d'analyse
Managing Principal (2020–Present)
Vice President (2014–2020)
Senior Economist (2010–2013)
Economist (2006–2009)
Intern (2005–2006)
- 2004 Quebec Revenue Agency, Ste-Foy (Agence Revenu Québec, Ste-Foy)
Intern in Economic and Fiscal Studies
- 2004 Ministry of Economic and Regional Research and Development, Quebec
(Ministère du Développement économique et régional et de la recherche, Québec)
Intern; conducted research on entrepreneurship in Quebec
- 2003 Ministry of Economic and Regional Research and Development, Quebec
(Ministère du Développement économique et régional et de la recherche, Québec)
Intern; performed structural analysis; researched promotion of R&D

PUBLICATIONS

2025

Kota V, Wei D, Yang D, Romdhani H, Latremouille-Viau D, **Guérin A**, Jadhav K. Non-optimal treatment with first tyrosine kinase inhibitor and associated economic burden in chronic myeloid leukemia. *J Med Econ*. 2025 Dec;28(1):743-752.

Tantravahi SK, Latremouille-Viau D, Desai R, Lee S, Paulose J, Geevarghese A, **Guérin A**, Seshasayee S, Chanpura M, Yen G. Real-World Prevalence and Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors in the US: A Retrospective Claims Database Analysis. *J Health Econ Outcomes Res*. 2025 Aug 15;12(2):66-74.

Wallace ZS, Park JY, Serra E, Gagnon-Sanschagrín P, **Guérin A**, Patterson K, Patel H, Singh VK. Burden of Glucocorticoid Use and Risk of Toxicities Among Patients with Immunoglobulin-G4-Related Disease: A Retrospective US-Based Claims Study. *Rheumatol Ther*. 2025 Jun;12(3):547-560.

Jesudian A, Gagnon-Sanschagrín P, Maitland J, Yokoji K, **Guérin A**, Heimanson Z, Samson A, Olujohungbe O, Bumpass B. Assessment of Access Barriers to Rifaximin Among Patients with Hepatic Encephalopathy Using Adjudicated Claims Data. *Adv Ther*. 2025 Jun;42(6):2739-2753.

Grossberg G, Willey C, Houle C, Schein J, Bungay R, Cloutier M, Gauthier-Loiselle M, Chan D, **Guérin A**, Ismail Z, Aggarwal J. Agitation in individuals with Alzheimer's disease: An assessment of behaviors using the cohen-mansfield agitation inventory in community-dwellers and impact on caregiver experience. *Dementia (London)*. 2025 May 14:14713012251340463. doi: 10.1177/14713012251340463.

Mayer EL, Smith ML, **Guérin A**, Latremouille-Viau D, Hazra NC, Meng Y, Qu W, Bellefleur R, Ganapathy V, Santarsiero L, Morlock R, Lustberg MB. Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast cancer: a discrete choice survey study. *Breast Cancer Res Treat*. 2025 May;211(1):121-130.

Wong RJ, Gagnon-Sanschagrín P, Heimanson Z, Maitland J, Bellefleur R, **Guérin A**, Samson A, Olujohungbe O, Bumpass B. Real-World Trends and Future Projections of the Prevalence of Cirrhosis and Hepatic Encephalopathy Among Commercially and Medicare-Insured Adults in the United States. *Clin Transl Gastroenterol*. 2025 May 1;16(5):e00823.

Li SS, D'Souza A, Lentzsch S, Zafar F, Pivneva I, Watson T, **Guérin A**, Kumar S. Treatment Patterns and Clinical Outcomes of Patients with Systemic Light Chain Amyloidosis in the United States: Evidence from Real-World Clinical Practice. *Clin Lymphoma Myeloma Leuk*. 2025 Mar 28:S2152-2650(25)00107-7. doi: 10.1016/j.clml.2025.03.012.

Flynn KE, Clements J, DeMairo K, Hiller J, Wei D, Hazra NC, Constantinescu C, Meng Y, Latremouille-Viau D, Jadhav K, Marquez G, Yang D, Damon A, Sadek I, **Guérin A**, Schoenbeck K. HSR25-174: Impact of Adverse Events on Quality of Life in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors - Results From the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study. *J Natl Compr Canc Netw*. 2025 Mar 28;23(3.5):HSR25-174. doi: 10.6004/jnccn.2024.7251.

Flynn KE, Clements J, DeMairo K, Hiller J, Wei D, Hazra NC, Constantinescu C, Meng Y, Latremouille-Viau D, Jadhav K, Marquez G, Yang D, Damon A, Sadek I, **Guérin A**, Schoenbeck K. HSR25-182: Patient-Physician Communication About Adverse Events and Impact on Quality of Life to Foster Shared Decision-Making in Chronic Myeloid Leukemia. *J Natl Compr Canc Netw*. 2025 Mar 28;23(3.5):HSR25-182.

Ghosh N, Eyre TA, Brown JR, Lamanna N, Manzoor BS, Coombs CC, Tuncer HH, Ujjani C, Leslie LA, Roeker LE, Davids MS, Rhodes JM, Skarbnik AP, Sinai W, Fleury I, Hill BT, Martinez-Calle N, Barr PM, Jawaid D, Emechebe N, Pearson L, Lansigan F, Choi Y, Jensen CE, Fakhri B, Stephens DM, Marx SE, Schuster SJ, Coyle M, Pivneva I, Watson T, **Guérin A**, Shadman M. Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic

Leukemia: An International Real-World Study. *Am J Hematol.* 2025 Mar;100(3):511-515.

Atallah EL, Wei D, Latremouille-Viau D, Rossi C, Damon A, Ferreira G, **Guérin A**, Jadhav K. Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States: Real-world asciminib treatment outcomes in CML-CP. *Clin Lymphoma Myeloma Leuk.* 2025 Mar;25(3):178-187.

2024

Feldman SR, **Guérin A**, Gauthier-Loiselle M, Claxton AJ, Hazra NC, Meng Y, Gallant K, Balu S. Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment. *J Dermatolog Treat.* 2024 Dec;35(1):2345739.

Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Chen K, Chan D, **Guérin A**, Childress A. Healthcare Resource Utilization and Costs Associated with Psychiatric Comorbidities in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder: A Claims-Based Case-Cohort Study. *Child Adolesc Psychiatry Ment Health.* 2024 Jul 8;18(1):80.

Hari P, Latremouille-Viau D, Lin P, **Guérin A**, Sasane M. Clinical and economic burden of medicare beneficiaries with multiple myeloma and renal impairment: An observational study. *Medicine (Baltimore).* 2024 Jun 28;103(26):e38609.

Yarur A, Mantzaris GJ, Wang S, Adsul S, Kamble P, Cook E, Sajeev G, **Guérin A**, Bressler B. Stratified Patient Profiling for Vedolizumab Effectiveness in Crohn's Disease: Identifying Optimal Subgroups for Enhanced Treatment Response in the EVOLVE Study. *Adv Ther.* 2024 Jun;41(6):2324-2341.

Lacy BE, Gagnon-Sanschagrín P, Heimanson Z, Bungay R, Bellefleur R, **Guérin A**, Bumpass B, Borroto D, Joseph G, Dashputre AA. Treatment-free interval: A novel approach to assessing real-world treatment effectiveness and economic impact among patients with irritable bowel syndrome with diarrhea. *Adv Ther.* 2024 Jun;41(6):2253-2266.

Chiorean M, Jiang J, Candela N, Chen G, Romdhani H, Latremouille-Viau D, Shi S, Bungay R, **Guérin A**, Fan T. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States. *Curr Med Res Opin.* 2024 May;40(5):877-885.

Davis LL, Urganus A, Gagnon-Sanschagrín P, Maitland J, Bedard J, Bellefleur R, Cloutier M, **Guérin A**, Aggarwal J. Patient journey of civilian adults diagnosed with posttraumatic stress disorder—a chart review study. *Curr Med Res Opin.* 2024 Jan 23;40(3):505-516. doi: 10.1080/03007995.2024.2308016. Online ahead of print.

Gagnon-Sanschagrín P, Sanon M, Davidson M, Willey C, Kachroo S, Hoops T, Naessens D, **Guérin A**, Cloutier M. The economic impact of suboptimal treatment and treatment switch among patients with Crohn's disease treated with a first-line biologic - A US retrospective claims database study. *J Med Econ.* 2024 Jan-Dec;27(1):931-940.

Grossberg G, Urganus A, Schein J, Bungay R, Cloutier M, Gauthier-Loiselle M, Chan D, **Guérin A**, Aggarwal J. A real-world assessment of healthcare costs associated with agitation in Alzheimer's dementia. *J Med Econ.* 2024 Jan-Dec;27(1):99-108.

2023

Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, Arpin E, **Guérin A**, Childress A. Risk factors associated with newly diagnosed attention-deficit/hyperactivity disorder in adults: a retrospective case-control study. *BMC Psychiatry.* 2023 Nov 23;23(1):870. Davis LL, Urganus A, Gagnon-Sanschagrín P, Maitland J, Qu W, Cloutier M, **Guérin A**, Aggarwal J. Patient journey before and after a formal post-traumatic stress disorder diagnosis in adults in the United States - a retrospective claims study. *Curr Med Res Opin.* 2023 Oct 10:1-10. doi: 10.1080/03007995.2023.2269839.

Jesudian AB, Gagnon-Sanschagrín P, Heimanson Z, Bungay R, Chen J, **Guérin A**, Bumpass B, Borroto D, Joseph G, Dashputre AA. Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs. *J Med Econ*. 2023 Sep 4;1-14.

Shadman M, Manzoor BS, Sail K, Tuncer HH, Allan JN, Ujjani C, Emechebe N, Kamalakar R, Coombs CC, Leslie L, Barr PM, Brown JR, Eyre TA, Rampotas A, Schuh A, Lamanna N, Skarbnik A, Roeker LE, Bannerji R, Eichhorst B, Fleury I, Davids MS, Alhasani H, Jiang D, Hill BT, Schuster SJ, Brander DM, Pivneva I, Burne R, **Guérin A**, Mato AR. Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. *Clin Lymphoma Myeloma Leuk*. 2023 Jul;23(7):515-526.

Schein J, Childress A, Gagnon-Sanschagrín P, Maitland J, Bedard J, Cloutier M, **Guérin A**. Treatment Patterns Among Patients with Attention-Deficit/Hyperactivity Disorder and Comorbid Anxiety and/or Depression in the United States: A Retrospective Claims Analysis. *Adv Ther*. 2023 May;40(5):2265-2281.

Sharma P, Falk GW, Bhor M, Ozbay AB, Latremouille-Viau D, **Guérin A**, Shi S, Elvekrog MM, Limburg P. Real-world upper endoscopy utilization patterns among patients with gastroesophageal reflux disease, Barrett esophagus, and Barrett esophagus-related esophageal neoplasia in the United States. *Medicine (Baltimore)*. 2023 Mar 24;102(12):e33072.

Sharma P, Falk GW, Bhor M, Ozbay AB, Latremouille-Viau D, **Guerin A**, Shi S, Elvekrog MM, Limburg P. Healthcare Resource Utilization and Costs Among Patients with Gastroesophageal Reflux Disease, Barrett's Esophagus, and Barrett's Esophagus-Related Neoplasia in the United States. *J Health Econ Outcomes Res*. 2023 Mar 3;10(1):51-58.

2022

Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, **Guérin A**, Childress A. Reasons for Treatment Changes in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Chart Review Study. *Adv Ther*. 2022 Dec;39(12):5487-5503. doi: 10.1007/s12325-022-02329-5. Epub 2022 Oct 11.

Schein J, Cloutier M, Gauthier-Loiselle M, Bungay R, **Guérin A**, Childress A. Symptoms associated with ADHD/treatment-related adverse side effects and their impact on quality of life and work productivity in adults with ADHD. *Curr Med Res Opin*. 2023 Jan;39(1):149-159. doi: 10.1080/03007995.2022.2122228. Epub 2022 Sep 30.

Gagnon-Sanschagrín P, Schein J, Urganus A, Serra E, Liang Y, Musingarimi P, Cloutier M, **Guérin A**, Davis LL. Identifying individuals with undiagnosed post-traumatic stress disorder in a large United States civilian population - a machine learning approach. *BMC Psychiatry*. 2022 Sep 29;22(1):630. doi: 10.1186/s12888-022-04267-6.

Davids MS, Manzoor B, Hazra N, Fang H, Ravelo A, Han F, **Guérin A**, Sail K, Shapouri S, Shadman M. The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia in the United States: A Cost of Care and Budget Impact Model of Venetoclax Plus Obinutuzumab Sequences. *J Clin Pathways*. 2022;8(5):36-46. doi:10.25270/jcp.2022.06.1.

Schein J, Childress A, Adams J, Gagnon-Sanschagrín P, Maitland J, Qu W, Cloutier M, **Guérin A**. Treatment Patterns Among Children and Adolescents with Attention- Deficit/Hyperactivity Disorder in the United States – A Retrospective Claims Analysis. *BMC Psychiatry*. 2022 Aug 18;22(1):555.

Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, **Guérin A**. Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective. *J Health Econ Outcomes Res*. 2022 Aug 4;9(2):30-36.

Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, **Guérin A**, Wu EQ, Patwardhan P. Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States. *J Health Econ Outcomes Res*. 2022 Aug 4;9(2):19-29.

Schein J, Childress A, Cloutier M, Desai U, Chin A, Simes M, **Guérin A**, Adams J. Reasons for treatment changes in adults with attention-deficit/hyperactivity disorder: a chart review study. *BMC Psychiatry*. 2022 Jun 3;22(1):377. doi: 10.1186/s12888-022-04016-9.

Davis LL, Schein J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Urganus A, **Guérin A**, Lefebvre P, Houle CR. The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal Perspective. *J Clin Psychiatry*. 2022 Apr 25;83(3):21m14116. doi: 10.4088/JCP.21m14116.

Peacock WF, Slatkin N, Gagnon-Sanschagrin P, Maitland J, **Guérin A**, Joseph G. Opioid-Induced Constipation: Cost Impact of Approved Medications in the Emergency Department. *Adv Ther*. 2022 May;39(5):2178-2191. doi: 10.1007/s12325-022-02090-9. Epub 2022 Mar 17.

Michalopoulos SN, Gauthier-Loiselle M, Aigbogun MS, Serra E, Bungay R, Clynes D, Cloutier M, Kahle E, **Guérin A**, Farag YMK, Wish JB. Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based Survey. *Kidney Med*. 2022 Mar 7;4(4):100439.

Schein J, Adler LA, Childress A, Cloutier M, Gagnon-Sanschagrin P, Davidson M, Kinkead F, **Guérin A**, Lefebvre P. Economic Burden of Attention-Deficit/Hyperactivity Disorder Among Children and Adolescents in the United States: A Societal Perspective. *J Med Econ*. Jan-Dec 2022;25(1):193-205. doi: 10.1080/13696998.2022.2032097.

2021

Gauthier-Loiselle M, Michalopoulos SN, Cloutier M, Serra E, Bungay R, Szabo E, **Guérin A**. Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective. *J Manag Care Spec Pharm*. 2021 Dec;27(12):1703-1713. doi: 10.18553/jmcp.2021.27.12.1703.

Schein J, Adler LA, Childress A, Gagnon-Sanschagrin P, Davidson M, Kinkead F, Cloutier M, **Guérin A**, Lefebvre P. Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective. *J Manag Care Spec Pharm*. 2022 Feb;28(2):168-179. doi: 10.18553/jmcp.2021.21290. Epub 2021 Nov 22.

Hariprasad SM, Joseph G, Gagnon-Sanschagrin P, Serra E, Bhattacharyya S, Bédard J, **Guérin A**, Albini TA. Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer's perspective. *BMJ Open Ophthalmol*. 2021 Nov 10;6(1):e000896. doi: 10.1136/bmjophth-2021-000896. eCollection 2021

Montoya V, Donnini K, Gauthier-Loiselle M, Sanon M, Cloutier M, Maitland J, **Guérin A**, Dutka P, Pryor L, Thomas-Hawkins C, Voegel A, Hoffmann M, Savin S, Kurzman A, Kear T. Mental Health and Health-Related Quality of Life Among Nephrology Nurses: A Survey-Based Cross-Sectional Study. *Nephrol Nurs J*. 2021 Sep-Oct;48(5):447-461.

Schein J, Houle C, Urganus A, Cloutier M, Patterson-Lomba O, Wang Y, King S, Levinson W, **Guérin A**, Lefebvre P, Davis LL. Prevalence of post-traumatic stress disorder in the United States: a systematic literature review. *Curr Med Res Opin*. 2021 Sep 9:1. doi: 10.1080/03007995.2021.1978417. Online ahead of print.

Schein J, Childress A, Adams J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, Bungay R, **Guérin A**, Lefebvre P. Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims study. *Curr Med Res Opin*. 2021 Aug 27:1-8. doi: 10.1080/03007995.2021.1968814. Online ahead of print

Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, Cloutier M, Davidson M, Serra E, **Guérin A**, Baker RA, Houle CR, Grossberg G. Impact of agitation in long-term care residents with dementia in the United States. *Int J Geriatr Psychiatry*. 2021 Jul 19. doi: 10.1002/gps.5604. Online ahead of print.

Meadows JA, Yu S, Hass SL, **Guérin A**, Latremouille-Viau D, Tilles SA. Health-care resource utilization associated with peanut allergy management under allergen avoidance among commercially insured individuals. *Allergy Asthma Proc*. 2021 Jul 1;42(4):333-342. doi: 10.2500/aap.2021.42.210047.

Atallah EL, Sadek I, Maegawa R, Cao X, Latremouille-Viau D, Pivneva I, Rossi C, **Guérin A**, Kota V. Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates. *Leuk Lymphoma*. 2021 Mar 1;1-14. doi: 10.1080/10428194.2021.1885656. Online ahead of print.

Chen L, Ionescu-Ittu R, Romdhani H, **Guérin A**, Kessler P, Borentain M, Friend K, DeSouza M, Sato N. Disease Management and Outcomes in Patients Hospitalized for Acute Heart Failure in Japan -

Cardiology and Therapy. *Cardiol Ther.* 2021 Feb 20. doi: 10.1007/s40119-021-00212-y. Online ahead of print.

Greene SJ, Triana TS, Ionescu-Ittu R, Shi S, **Guérin A**, DeSouza MM, Kessler PD, Tugcu A, Borentain M, Felker GM. Patients Hospitalized for De Novo versus Worsening Chronic Heart Failure in the United States. *J Am Coll Cardiol.* 2021 Feb 23;77(7):1023-1025. doi: 10.1016/j.jacc.2020.12.026.

Gagnon-Sanschagrin P, Liang Y, Sanon M, Oberdhan D, **Guérin A**, Cloutier M. Excess Healthcare Costs in Patients with Autosomal Dominant Polycystic Kidney Disease by Renal Dysfunction Stage. *J Med Econ.* 2021 Jan-Dec;24(1):193-201. doi: 10.1080/13696998.2021.1877146.

Burne R, Balu S, **Guérin A**, Bungay R, Sin R, Paul ML. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors. *J Med Econ.* 2021 Jan-Dec;24(1):806-815. doi: 10.1080/13696998.2021.1939705.

Volk ML, Burne R, **Guérin A**, Shi S, Joseph GJ, Heimanson Z, Ahmad M. Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States. *J Med Econ.* 2021 Jan-Dec;24(1):202-211. doi: 10.1080/13696998.2021.1877148.

Stein EM, Bonifacio G, Latremouille-Viau D, Shi S, **Guérin A**, Wu EQ, Sadek I, Cao X. Healthcare Resource Utilization and Costs in Patients with Myelodysplastic Syndrome Treated with Hypomethylating Agents: A SEER-Medicare Analysis. *J Med Econ.* 2021 Jan-Dec;24(1):234-243. doi: 10.1080/13696998.2021.1876714.

Blais MS, Meadows JA, Yu S, Robison DR, Hass SL, Norrett KE, **Guérin A**, Latremouille-Viau D, Tilles SA. Economic Burden of Peanut Allergy in Pediatric Patients with Evidence of Reactions to Peanut in the United States. *J Manag Care Spec Pharm.* 2021 Jan 20:1-12. doi: 10.18553/jmcp.2021.20389. Online ahead of print. PMID: 33470880.

Stein EM, Bonifacio G, Latremouille-Viau D, Shi S, **Guérin A**, Wu EQ, Sadek I, Cao X. Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. *Leuk Lymphoma.* 2021 Jan 11;1-16. doi: 10.1080/10428194.2020.1869959. Online ahead of print.

2020

Aigbogun MS, Cloutier M, Gauthier-Loiselle M, **Guérin A**, Ladouceur M, Baker RA, Grundman M, Duffy RA, Hartry A, Gwin K, Fillit H. Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review. *J Alzheimers Dis.* 2020;77(3):1181-1194. doi: 10.3233/JAD-200127.

Shah NR, Bhor M, Latremouille-Viau D, Kumar Sharma V, Puckrein GA, Gagnon-Sanschagrin P, Khare A, Kumar Singh M, Serra E, Davidson M, Xu L, **Guérin A**. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid and Medicare Insurance - The perspective of private and public payers. *J Med Econ* 2020 Nov;23(11):1345-1355. doi: 10.1080/13696998.2020.1813144.

Glick B, **Guérin A**, Ayyagari R, Lin T, Jacobson A, Joseph G, Kircik L. Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis. *J Med Econ.* 2020. 23:6, 641-649. *J Med Econ.* 2020 Oct 12:1. doi: 10.1080/13696998.2020.1835305. Online ahead of print.

Greene SJ, Triana TS, Ionescu-Ittu R, Burne RM, **Guérin A**, Borentain M, Kessler PD, Tugcu A, DeSouza MM, Felker GM, Chen L. In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States. *JACC Heart Fail.* 2020 Aug 12:S2213-1779(20)30383-8. doi: 10.1016/j.jchf.2020.05.013. Online ahead of print.

Cloutier M, Manceur AM, **Guérin A**, Aigbogun MS, Oberdhan D, Gauthier-Loiselle M. The societal

economic burden of autosomal dominant polycystic kidney disease in the United States. *BMC Health Serv Res.* 2020 Feb 18;20(1):126. doi: 10.1186/s12913-020-4974-4.

2019

Mohr P, Kiecker F, Soriano V, Dereure O, Mujika K, Saiag P, Utikal J, Koneru R, Robert C, Cuadros F, Chacón M, Villarroel RU, Najjar YG, Kottschade L, Couselo EM, Koruth R, **Guérin A**, Burne R, Ionescu-Ittu R, Perrinjaquet M, Zager JS. Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. *Melanoma Manag.* 2019 Oct 4;6(4):MMT33. doi: 10.2217/mmt-2019-0015.

Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrín P, **Guérin A**, Hartry A, Baker RA, Duffy R, Gwin K, Sanon Aigbogun M. Institutionalization risk and costs associated with agitation in Alzheimer's disease. *Alzheimers Dement (NY).* 2019 Nov 23;5:851-861. doi: 10.1016/j.trci.2019.10.004. eCollection 2019.

Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, **Guérin A**, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. *Adv Ther* (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8. *Adv Ther.* 2019 Nov;36(11):2982-2985. doi: 10.1007/s12325-019-01088-0. Epub 2019 Sep 11.

Ionescu-Ittu R, Shang A, Velde NV, **Guérin A**, Lin Y, Shi L, Shi S, Qayum N. Second-line rituximab-bendamustine versus rituximab-gemcitabine-oxaliplatin in diffuse large B-cell lymphoma in the real world. *J Comp Eff Res.* 2019 Oct;8(13):1067-1075. doi: 10.2217/cer-2019-0062. Epub 2019 Aug 27. PMID: 31452397. Free article. <https://pubmed.ncbi.nlm.nih.gov/31452397/>.

Ionescu-Ittu R, Shang A, Vander Velde N, **Guérin A**, Lin Y, Shi L, Shi S, Qayum N. Comparable Overall Survival with Rituximab-Bendamustine (R-Benda) and Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) When Used As Second-Line (2L) Treatment for Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World Study Using US Veterans Health Administration Data. *Blood Journal.* 2019. http://www.bloodjournal.org/content/132/Suppl_1/1711? Epub ahead of print.

Pennell N, Mutebi A, Zhou ZY, Ricculli ML, Tang W, Wang H, **Guérin A**, Arnhart T, Dalal A, Sasane M, Wu KY, Culver KW, Otterson GA. Economic Impact of Next Generation Sequencing vs. Single-gene Testing Strategies to Detect Genomic Alterations in Metastatic NSCLC Using a Decision Analytic Model. *JCO Precision Oncology.* 2019 May 16. doi: 10.1200/PO.18.00356. Epub ahead of print.

Dana R, Bradley JL, **Guérin A**, Pivneva I, Stillman IÖ, Evans AM, Schaumberg DA. Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System. *Am J Ophthalmol.* 2019 Jun;202:47-54.

Ritchie EK, Latremouille-Viau D, **Guérin A**, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL. Tyrosine Kinase Inhibitor Therapy Treatment and Discontinuation in Patients with Chronic Myeloid Leukemia in Chronic Phase in the United States: a Clinical Practice Perspective. *Leuk Lymphoma*. 2019 Jun;60(6):1476-1484.

Gauthier G, Mucha L, Shi S, **Guérin A**. Economic burden of relapse/recurrence in patients with major depressive disorder. *J Drug Assess*. 2019 May 24;8(1):97-103.

Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, **Guérin A**, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Survival, Motor Function, and Motor Milestones Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1. *Adv Ther*. 2019 May;36(5):1164-1176.

Bradley JL, Özer Stillman I, Pivneva I, **Guérin A**, Evans AM, Dana R. Dry eye disease ranking among common reasons for seeking eye care in a large US claims database. *Clin Ophthalmol*. 2019 Feb 1;13:225-232.

Stein E, Xie J, Duchesneau E, Bhattacharyya S, Vudumula U, Ndife B, Bonifacio G, **Guérin A**, Li N, Joseph G. Cost-effectiveness of Midostaurin in the Treatment of Newly diagnosed FLT3-mutated Acute Myeloid Leukemia in the United States. *Pharmacoeconomics*. 2019 Feb;37(2):239-253.

Vander Velde N, **Guérin A**, Ionescu-Ittu R, Shi S, Wu EQ, Lin SW, Hsu LI, Saum KU, de Ducla S, Wang J, Li S, Thåström A, Liu S, Shi L, Leppert JT. Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration. *Eur Urol Oncol*. 2019 Feb;2(1):12-20.

Lacy B, Ayyagari R, **Guérin A**, Lopez A, Shi S, Luo M. Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome. *Therap Adv Gastroenterol*. 2019 Jan 1;12:1756284818818326. doi: 10.1177/1756284818818326.

2018

Kimball AB, Sundaram M, Gauthier G, **Guérin A**, Pivneva I, Singh R, Ganguli A. The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis. *Dermatol Ther (Heidelb)*. 2018 Dec;8(4):557-569.

Wu J, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrín P, Arian D, Fleischer A, **Guérin A**, Ganguli A. Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis. *J Drugs Dermatol*. 2018 Nov 1;17(11):1211-1218.

Seiter K, Latremouille-Viau D, **Guérin A**, Ndife B, Habucky K, Tang DH, Pivneva I, Gagnon-Sanschagrín P, Joseph GJ. Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States. *Adv Ther*. 2018 Oct;35(10):1671-1685.

Dana R, Bradley JL, **Guérin A**, Pivneva I, Evans AM, Stillman IÖ. Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based Study. *Am J Ophthalmol*. 2019 Feb;198:181-192. doi: 10.1016/j.ajo.2018.10.001. Epub 2018 Oct 9.

Cloutier M, Greene M, Touya M, Gagnon-Sanschagrín P, **Guérin A**. A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United States. *J Med Econ*. 2018 Sep 26:1-8.

Stein EM, Yang M, **Guérin A**, Gao W, Galebach P, Xiang CQ, Bhattacharyya S, Bonifacio G, Joseph GJ. Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States. *Health Qual Life Outcomes*. 2018 Sep 21;16(1):193.

Dalal AA, Gauthier G, Gagnon-Sanschagrín P, Burne R, **Guérin A**, Niravath P, Small T. Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer. *Adv Ther*. 2018 Sep;35(9):1356-1367.

Guérin A, Goldschmidt D, Small T, Gagnon-Sanschagrín P, Romdhani H, Gauthier G, Kelkar S, Wu EQ, Niravath P, Dalal AA. Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer. *Adv Ther*. 2018 Aug;35(8):1251-1264.

Reyes C, Gauthier G, Shi S, **Guérin A**. Overall Survival and Health Care Costs of Medicare Patients with Previously Treated Chronic Lymphocytic Leukemia. *Journal of Cancer Therapy*. 2018 Jul;9(7)..

Dalal AA, Gagnon-Sanschagrín P, Burne R, **Guérin A**, Gauthier G, Small T, Niravath P. Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer. *Adv Ther*. 2018 Jun;35(6):768-778.

Borghaei H, Yim YM, **Guérin A**, Pivneva I, Shi S, Gandhi M, Ionescu-Ittu R. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. *Lung Cancer*. 2018 May;119:112-119.

Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrín P, **Guérin A**. Assessment of costs associated with adverse events in patients with cancer. *PLoS One*. 2018 Apr 13;13(4):e0196007.

Gauthier G, Gagnon-Sanschagrín P, **Guérin A**, Burne R, Small T, Niravath P, Dalal AA. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women. *Adv Ther*. 2018 Apr;35(4):503-514.

Goldschmidt D, Dalal AA, Romdhani H, Kelkar S, **Guérin A**, Gauthier G, Wu EQ, Niravath P, Small T. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study. *Adv Ther*. 2018 Apr;35(4):482-493.

Dalal AA, **Guérin A**, Mutebi A, Culver KW. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer. *J Med Econ*. 2018 Mar 26:1-7.

Dalal AA, **Guérin A**, Mutebi A, Culver KW. Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis. *J Drug Assess*. 2018 Mar 12;7(1):21-27.

Kimball AB, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrín P, **Guérin A**, Ganguli A. Increased Prevalence of Cancer in Adult Patients with Psoriasis in the United States: A Claims Based Analysis. *J Drugs Dermatol*. 2018 Feb 1;17(2):180-186.

Imafuku S, Nakano A, Dakeshita H, Li J, Betts KA, **Guérin A**. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan. *J Dermatolog Treat*. 2018 Feb;29(1):24-31.

Nellesen D, Dea K, **Guérin A**, Culver KW, Mutebi A, Dalal AA. Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer (NSCLC). *Am J Manag Care*. 2018 Feb;24(2 Spec No.):SP37-SP42. <http://www.ajmc.com/journals/evidence-based-oncology/2018/february-2018/reimbursement-landscape-for-molecular-testing-in-nonsmall-cell-lung-cancer?p=1>.

Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, **Guérin A**, Singh R, Ganguli A. The Risk of Cardiovascular Events in Psoriasis Patients Treated with Tumor Necrosis Factor-alpha Inhibitors

versus Phototherapy: A Large Observational Cohort Study. *J Am Acad Dermatol*. 2018 Feb 27. pii: S0190-9622(18)30335-9.

Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, **Guérin A**, Ganguli A. Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis. *J Drugs Dermatol*. 2018 Feb 1;17(2):187-194.

Stein EM, Bonifacio G, Latremouille-Viau D, **Guérin A**, Shi S, Gagnon-Sanschagrín P, Briggs O, Joseph GJ. Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Acute Myeloid Leukemia in Commercially Insured and Medicare Populations. *J Med Econ*. 2018 Jan 5:1-17.

2017

Johnson DR, Omuro AMP, Ravelo A, Sommer N, **Guérin A**, Ionescu-Ittu R, Shi S, Macalalad A, Uhm JH. Overall survival in patients with glioblastoma before and after bevacizumab approval. *Curr Med Res Opin*. 2017 Nov 10:1-8.

Yang H, Duchesneau E, Foster R, **Guérin A**, Ma E, Thomas NP. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. *J Med Econ*. 2017 Oct;20(10):1056-1065.

Maziarz RT, Hao Y, **Guérin A**, Gauthier G, Gauthier-Loiselle M, Thomas SK, Eldjerou L. Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2017 Sep 21:1-10.

Cloutier M, Greene M, **Guérin A**, Touya M, Wu E. The economic burden of bipolar I disorder in the United States in 2015. *J Affect Disord*. 2017 Sep 14;226:45-51.

Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, **Guérin A**. Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients. *Adv Ther*. 2017 Jul;34(7):1673-1685.

Gauthier G, **Guérin A**, Zhdanova M, Jacobson W, Nomikos G, Merikle E, François C, Perez V. Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis. *BMC Psychiatry*. 2017 Jun 19;17(1):222.

Wu JJ, **Guérin A**, Gauthier G, Sundaram M. Healthcare Resource Utilization, Healthcare Costs, and Dose Escalation in Psoriasis Patients Initiated on Ustekinumab versus Adalimumab: A Retrospective Claim Study. *J Dermatolog Treat*. 2017 Jun;28(4):290-298.

Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, **Guérin A**. Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study. *Adv Ther*. 2017 May;34(5):1145-1156.

Li N, Yang X, Fan L, Totev T, **Guérin A**, Chen L, Bhattacharyya S, Joseph G. Nilotinib versus Dasatinib as Second-Line Therapy in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis Based on Real-World Data. *J Med Econ*. 2017 Apr;20(4):328-336.

Bollu V, **Guérin A**, Gauthier G, Hiscock R, Wu EQ. Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized β 2-Agonists. *Drugs Real World Outcomes*. 2017 Mar;4(1):33-41.

Ritchie EK, **Guérin A**, Wolff J, Joseph G. Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries With Chronic Myeloid Leukemia. *J Clin Oncol*. 2017 May 20;35(15):1744-1745. doi: 10.1200/JCO.2016.72.0011. Advance online publication 2017 Feb 13. No abstract available.

Latremouille-Viau D, **Guérin A**, Gagnon-Sanschagrín P, Dea K, Cohen BG, Joseph GJ. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency. *J Manag Care Spec Pharm*. 2017 Feb;23(2):214-224.

Wu JJ, **Guérin A**, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor- α inhibitors versus methotrexate. *J Am Acad Dermatol*. 2017 Jan;76(1):81-90.

Latremouille-Viau D, **Guérin A**, Nitulescu R, Gagnon PS, Joseph GJ, Chen L. Treatment Patterns and Healthcare Costs among Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as First-Line Therapy in the United States. *J Med Econ*. 2017 Jan;20(1):63-71.

Latremouille-Viau D, Chang J, **Guérin A**, Shi S, Wang E, Yu J, Ngai C. The Economic Burden of Common Adverse Events Associated with Metastatic Colorectal Cancer Treatment in the United States. *J Med Econ*. 2017 Jan;20(1):54-62.

2016

Jemec GB, **Guérin A**, Kaminsky M, Okun M, Sundaram M. What happens after a single surgical intervention for hidradenitis suppurativa? A retrospective claims-based analysis. *J Med Econ*. 2016 Jul;19(7):710-7.

Cloutier M, Sanon Aigbogun M, **Guérin A**, Nitulescu R, Ramanakumar AV, Kamat SA, DeLucia M, Duffy R, Legacy SN, Henderson C, Francois C, Wu E. The Economic Burden of Schizophrenia in the United States in 2013. *J Clin Psychiatry*. 2016 Jun;77(6):764-71.

Guérin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry A, Koo V, Li N, Wu EQ. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study. *Expert Opin Pharmacother*. 2016 Jun;17(9):1189-96.

Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, **Guérin A**. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. *Adv Ther*. 2016 Jun;33(6):983-97.

Gallagher CM, More K, Kamath T, Masaquel A, **Guérin A**, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, Sicignano N, Butts E, Wu EQ, Barnett B. Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer. *Breast Cancer Res Treat*. 2016 May;157(1):145-56.

Maziarz RT, **Guérin A**, Gauthier G, Heroux J, Zhdanova M, Wu EQ, Thomas SK, Chen L. Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell

transplant. *Int J Hematol Oncol*. Advance online publication 2016 Apr 27. doi: 10.2217/ijh-2016-0001.

Lacy BE, Patel H, **Guérin A**, Dea K, Scopel JL, Alaghband R, Wu EQ, Mody R. Variation in Care for Patients with Irritable Bowel Syndrome in the United States. *PLoS One*. 2016 Apr 26;11(4):e0154258.

Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, **Guérin A**. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. *J Med Econ*. 2016 Apr;19(4):414-23.

Gallagher CM, More K, Masaquel A, Kamath T, **Guérin A**, Ionescu-Ittu R, Nitulescu R, Gauthier-Loiselle M, Sicignano N, Butts E, Wu EQ, Barnett B. Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice. *Springerplus*. 2016 Mar 31;5:395.

Joseph A, Cloutier M, **Guérin A**, Nitulescu R, Sikirica V. Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine or atomoxetine. *Patient Prefer Adherence*. 2016 Mar 24;10:391-405.

Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, **Guérin A**. Time on treatment of everolimus and chemotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: A retrospective claims study in the US. *Curr Med Res Opin*. 2015 Dec 10:1-32. *Curr Med Res Opin*. 2016 Feb;32(2):385-94.

Smith BD, Liu J, Latremouille-Viau D, **Guérin A**, Fernandez D, Chen L. Treatment Patterns, Overall Survival, Healthcare Resource Use and Costs in Elderly Medicare Beneficiaries with Chronic Myeloid Leukemia using Second-Generation Tyrosine Kinase Inhibitors as Second-Line Therapy. *Curr Med Res Opin* 2016 32(5): 817-827. Advance online publication 2016 Jan 9; doi: 10.1185/03007995.2016.1140030.

Guérin A, Mody R, Carter V, Ayas C, Patel H, Lasch K, Wu E. Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication. *PLoS One*. 2016 Jan 4;11(1):e0145504.

Guérin A, Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, Wu EQ, Macalalad AR. The economic burden of brain metastasis among lung cancer patients in the United States. *J. Med. Econ*. 2016 05; 19(5): 526-536. doi: 10.3111/13696998.2016.1138962.

2015

Guérin A, Sasane M, Keir CH, Gauthier G, Macalalad AR, Wu EQ, Conley AP. Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection. *JAMA Oncol*. 2015 Sep;1(6):797-805.

Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Abhyankar S, Reyes C, **Guérin A**, Yim YM. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting. *Cancer Med*. 2015 Aug;4(8):1205-13.

Guérin A, Sasane M, Wakelee H, Zhang J, Culver K, Dea K, Nitulescu R, Galebach P, Macalalad AR. Treatment, overall survival and costs in patients with ALK+ non-small cell lung cancer after crizotinib monotherapy. *Curr Med Res Opin*. 2015 Aug;31(8):1587-97.

Shiozawa A, Cloutier M, Heroux J, **Guérin A**, Wu EQ, Jackson R. Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study. *Curr Med Res Opin*. 2015 Aug;31(8):1611-20.

Armstrong AW, **Guérin A**, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. *J Am Acad Dermatol*. 2015 Jun;72(6):968-977.

Guérin A, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Culver K, Wu EQ, Wakelee H. ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. *Cancer Epidemiol*. 2015 Jun;39(3):307-12.

Guérin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, Wu EQ. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. *J Med Econ*. 2015 Apr;18(4):312-22.

Guérin A, Sasane M, Gauthier G, Keir CH, Zhdavana M, Wu EQ. The Economic Burden of Gastrointestinal Stromal Tumor (GIST) Recurrence in Patients Who Have Received Adjuvant Imatinib Therapy. *J Med Econ*. 2015 Mar;18(3):241-8.

2014

Conley AP, **Guérin A**, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ. Treatment Patterns, Prescribing Decision Drivers, and Predictors of Complete Response Following Disease Recurrence in Gastrointestinal Stromal Tumor Patients-a Chart Extract-Based Approach. *J Gastrointest Cancer*. 2014 Dec;45(4):431-40.

Langer C, Ravelo A, Hazard SJ, **Guérin A**, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: A retrospective cohort study. *Lung Cancer*. 2014 Dec;86(3):350-7.

Mody R, **Guérin A**, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ. Prevalence and Risk of Developing Comorbid Conditions in Patients with Chronic Constipation. *Curr Med Res Opin*. 2014 Dec;30(12):2505-2513.

Guérin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, Keir C, Wu EQ. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. *Curr Med Res Opin*. 2014 Nov;30(11):2317-28.

Loftus EV Jr, Skup M, Ozbay AB, Wu E, **Guérin A**, Chao J, Mulani P. The Impact of Moderate-to-severe Crohn's Disease on Employees' Salary Growth. *Inflamm Bowel Dis*. 2014 Oct;20(10):1734-8.

Bron M, **Guérin A**, Latremouille-Viau D, Ionescu-Ittu R, Viswanathan P, Lopez C, Wu EQ. Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis. *J Med Econ*. 2014 Sep;17(9):646-57.

Hurvitz S, **Guérin A**, Brammer M, Guardino E, Zhou ZY, Latremouille Viau D, Wu EQ, Lalla D. Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting. *Oncologist*. 2014 Sep;19(9):901-8.

Guérin A, Carson RT, Lewis B, Yin D, Kaminsky M, Wu E. The Economic Burden of Treatment Failure Among Patients with Irritable Bowel Syndrome with Constipation or Chronic Constipation: A Retrospective Analysis of a Medicaid Population. *J Med Econ*. 2014 Aug;17(8):577-86.

Deangelo DJ, Chen L, **Guérin A**, Styles A, Giguere-Duval P, Wu EQ. Impact of Timely Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor After 12-Month Complete Cytogenetic Response Failure: A Chart Review Analysis. *Clin Lymphoma Myeloma Leuk*. 2014 Jun;14(3):245-51.

Guérin A, Chen L, Dea K, Wu EQ, Goldberg SL. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. *Curr Med Res Opin*. 2014 Jul;30(7):1345-52.

Guérin A, Mody R, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ. Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation. *Aliment Pharmacol Ther*. 2014 Jul;40(1):83-92.

Guérin A, Lalla D, Gauthier G, Styles A, Wu EQ, Masaquel A, Brammer MG. Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis. *Springerplus*. 2014 May 8;3:236.

Guérin A, Chen L, Dea K, Wu EQ, Goldberg SL. Economic Benefits of Adequate Molecular Monitoring in Patients with Chronic Myelogenous Leukemia. *J Med Econ*. 2014 Feb;17(2):89-98.

Ben Amor L, Sikirica V, Cloutier M, Lachaine J, **Guérin A**, Carter V, Hodgkins P, van Stralen J. Combination and switching of stimulants in children and adolescents with ADHD in Quebec. *J Can Acad Child Adoles Psychiatry*. 2014;23(3):157-166.

2013

Setyawan J, **Guérin A**, Hodgkins P, Gauthier G, Cloutier M, Wu E, Haim Erder M. Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications. *J Med Econ*. 2013 Nov;16(11):1275-89.

Setyawan J, Hodgkins P, **Guérin A**, Gauthier G, Cloutier M, Wu E, Erder MH. Comparison of Therapy Augmentation and Deviation Rates from the Recommended Once-Daily Dosing Regimen between LDX and Commonly Prescribed Long-Acting Stimulants for the Treatment of ADHD in Youth and Adults. *J Med Econ*. 2013 Oct;16(10):1203-15.

Goldberg SL, Chen L, **Guérin A**, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ. Association between Molecular Monitoring and Long Term Outcomes in Chronic Myelogenous Leukemia Patients Treated with First Line Imatinib. *Curr Med Res Opin*. 2013 Sep;29(9):1075-82.

Guérin A, Lin J, Jhaveri M, Wu EQ, Yu AP, Cloutier M, Gauthier G, Alpert JS. Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy. *Int J Cardiol*. 2013 Jul 31;167(2):564-9.

Kan H, **Guérin A**, Kaminsky MS, Yu AP, Wu EQ, Denio A, Priti J, Narayanan S, Molta C. A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus. *J Med Econ*. 2013 Jul;16(7):962-75.

Setyawan J, Hodgkins P, **Guérin A**, Gauthier G, Cloutier M, Wu EQ, Haim Erder M. Comparing Treatment Adherence of Lisdexamfetamine and Other Medications for the Treatment of Attention Deficit/Hyperactivity Disorder: A Retrospective Analysis. *J Med Econ*. 2013 Jul;16(7):962-75.

Conley AP, **Guérin A**, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ. Comparison of the Long-Term Risk of Recurrence and Other Clinical Outcomes in GIST Patients Receiving Imatinib as Adjuvant Therapy-A Retrospective Chart Extract-Based Approach. *J Gastrointest Cancer*. 2013 Jun;44(2):190-8.

Griffin JD, **Guérin A**, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, Wu EQ. Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib - a retrospective chart review analysis. *Curr Med Res Opin.* 2013 Jun;29(6):623-31.

Guérin A, Wu EQ, Bollu VK, Williams D, Guo A, de Leon DP, Quintas-Cardama A. The Economic Burden of Pleural Effusions in Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors. *J Med Econ.* 2013;16(1):125-33.

2012

Strober BE, Sobell JM, Duffin KC, Bao Y, **Guérin A**, Yang H, Goldblum O, Okun MM, Mulani PM. Sleep quality and other patient-reported outcomes improve after psoriasis patients with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. *Br J Dermatol.* 2012 Dec;167(6):1374-81.

Ray S, Bonthapally V, Holen KD, Gauthier G, Wu EQ, Cloutier M, **Guérin A**. Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors. *J Med Econ.* 2012 Nov 16. 2013;16(2):221-30.

Chen L, **Guérin A**, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E. Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis. *Curr Med Res Opin.* 2012 Nov;28(11):1831-9.

Wu EQ, Forsythe A, **Guérin A**, Yu AP, Latremouille-Viau D, Tsaneva M. Comorbidity Burden, Healthcare Resource Utilization, and Costs in Chronic Gout Patients Refractory to Conventional Urate-Lowering Therapy. *Am J Ther.* 2012 Nov;19(6):e157-66.

Kimball AB, Wu EQ, **Guérin A**, Yu AP, Tsaneva M, Gupta SR, Bao Y, Mulani PM. Risks of developing psychiatric disorders in pediatric patients with psoriasis. *J Am Acad Dermatol.* 2012 Oct;67(4):651-7.e1-2.

Helmerts SL, Duh MS, **Guérin A**, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E. Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy. *Eur J Paediatr Neurol.* 2012 Sep;16(5):449-58.

Guérin A, Chen L, Wu EQ, Ponce de Leon D, Griffin JD. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. *Curr Med Res Opin.* 2012 Jul;28(7):1155-62.

Cella D, Pickard AS, Duh MS, **Guérin A**, Mishagina N, Antràs L, Neary MP, McCann L, Hodge R, Sternberg CN. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. *Eur J Cancer.* 2012 Feb;48(3):311-23.

2011

Yu AP, **Guérin A**, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum SI, Setyawan J. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. *Respir Med.* 2011 Dec;105(12):1861-71.

Helmerts SL, Duh MS, **Guérin A**, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E. Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. *Epilepsy Behav.* 2011 Oct;22(2):370-5.

Loftus EV Jr, **Guérin A**, Yu AP, Wu EQ, Yang M, Chao J, Mulani PM. Increased Risks of Developing Anxiety and Depression in Young Patients With Crohn's Disease. *Am J Gastroenterol*. 2011 Sep;106(9):1670-7.

Yu AP, **Guérin A**, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. *J Med Econ*. 2011 June;14(4):486-96.

Kimball AB, Bensimon AG, **Guérin A**, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM. Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities: Subanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. *Am J Clin Dermatol*. 2011 Feb 1;12(1):51-62.

Kimball AB, **Guérin A**, Tsaneva M, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM. Economic Burden of Comorbidities in Patients with Psoriasis Is Substantial. *J Eur Acad Dermatol Venereol*. 2011 Feb;25(2):157-163.

Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, **Guérin A**, Boerstoeel-Streefland M, Jiang W, Lefebvre P. Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data. *Ann Pharmacother*. 2011 Feb;45(2):179-88.

Duh MS, Greenberg PE, **Guérin A**, Korves C. Mortality and nonadherence to AEDs (chapter), *Sudden Unexpected Death in Epilepsy: Continuing the Global Conversation*, a publication of Epilepsy Australia, Epilepsy Bereaved, and SUDEP Aware/North America, 2011.

2010

Wu EQ, **Guérin A**, Yu AP, Bollu VK, Guo A, Griffin JD. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. *Curr Med Res Opin*. 2010 Dec;26(12):2861-9.

Frois C, **Guérin A**, Saraogi A, Panish J, Dirani R. Perceptions and prescribing considerations among US psychiatrists regarding drug-drug interactions associated with oral atypical antipsychotics. *Curr Med Res Opin*. 2010 Dec;26(12):2735-44.

Kimball AB, **Guérin A**, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P. Coronary Heart Disease and Stroke Risk in Patients with Psoriasis: Retrospective Analysis. *Am J Med*. 2010 Apr;123(4):350-357.

Saurat JH, **Guérin A**, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, Bao Y, Mulani PM. High Prevalence of Potential Drug-Drug Interactions for Psoriasis Patients Prescribed Methotrexate or Cyclosporine for Psoriasis: Associated Clinical and Economic Outcomes in Real-World Practice. *Dermatology*. 2010;220(2):128-37.

2009

Faught RE, Weiner JR, **Guérin A**, Cunnington MC, Duh MS. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: Findings from the RANSOM study. *Epilepsia*. 2009 Mar;50(3):501-9.

Loftus EV, **Guérin A**, Tsaneva M, Yu AP, Chao JD, Mulani P. Direct and Indirect Economic Burdens and Impact on Salary Growth of Moderate to Severe Crohn's Disease. *Gastroenterology*. 2009; 136(5):A-26-27.

2008

Faught E, Duh MS, Weiner JR, **Guérin A**, Cunnington MC., Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study, *Neurology*. 2008 Nov 11;71(20):1564-5.

Cost-Effectiveness Analysis of Different Hormonal Therapies in Breast Cancer in Women (master's thesis), Université de Sherbrooke, Quebec, 2008.

LANGUAGES

French (native)

English (fluent)